This inventor holds 41 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent, primarily in Prostate Cancer Treatment. Top assignees: Nymox Corporation, Nymox Pharmaceutical Corporation, Dms Pharmaceutical Inc.. Active years: 1989-2023.
Location History:
- Montreal, CA (1989 - 2004)
- St. Laurent, CA (2007)
- Quebec, CA (1990 - 2009)
- Beaconsfield, CA (1996 - 2016)
- Nassau, BS (2019 - 2023)
Company Filing History:
25 out of 29 
8 out of 8 
3 out of 3 
Years Active: 1989-2023
Areas of Expertise:
Title: Paul A Averback: Innovator in Minimally Invasive Treatments
Introduction
Paul A Averback is a prolific inventor based in Quebec, Canada, known for his significant contributions to the field of medicine. With an impressive portfolio of 37 patents to his name, Averback has made notable advancements in minimizing the need for invasive surgical procedures. His groundbreaking work focuses primarily on the treatment of conditions such as benign prostatic hyperplasia and prostate cancer.
Latest Patents
Among his latest innovations, Averback has developed methods for reducing the need for surgery in patients suffering from benign prostatic hyperplasia. This patent features a unique approach utilizing small peptides combined with additional active agents to treat conditions that necessitate the removal or destruction of cellular elements. The described methods allow for various administration routes, including intramuscularly, orally, intravenously, and even topically, effectively reducing the need for invasive surgical interventions.
Another significant patent of Averback addresses the treatment of prostate cancer. This method involves administering a composition that includes a therapeutically effective amount of active ingredients capable of inducing necrosis of low-grade unifocal prostate tumors. The innovation promises to reduce cancer incidence, grade, and progression throughout the affected area, showcasing Averback's commitment to advancing cancer treatment.
Career Highlights
Paul A Averback has held key roles at Nymox Corporation and Nymox Pharmaceutical Corporation, where he has contributed to the development of innovative medical solutions. His expertise in the field has allowed him to thrive and drive forward impactful projects within these organizations.
Collaborations
Throughout his career, Averback has collaborated with several notable colleagues, including Jack Gemmell and Hossein A Ghanbari. These partnerships have facilitated the exchange of ideas and propelled the advancement of their shared goals in medical innovation.
Conclusion
With a remarkable number of patents and a commitment to improving patient outcomes, Paul A Averback stands out as a leading inventor in the realm of minimally invasive medical treatments. His innovative methods have the potential to alter the landscape of treatment for benign prostatic hyperplasia and prostate cancer, contributing greatly to the future of healthcare.